AuB is an intestinal microflora analysis that contributes to the athlete's performance improvement and human health maintenance.
AuB has raised $4.9M in total funding. The most recent round was Series C. The last funding was announced in May 2024.
AuB's investors include Mitsubishi UFJ Capital, Shizuoka Capital, Kyocera, Taiho Pharmaceutical, Fundinno.
AuB is headquartered in Ginza, Japan.
AuB is an intestinal microflora analysis that contributes to the athlete's performance improvement and human health maintenance.
AuB is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AuB — Funding & Investors." VCBacked, May 31, 2024, https://www.vcbacked.co/company/aub. Accessed November 13, 2026.
VCBacked. (2024). AuB — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/aub
{{cite web |title=AuB — Funding & Investors |url=https://www.vcbacked.co/company/aub |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at AuB? Request a listing update